- Ongoing, recruitingTherapeutic exploratory (Phase II)
CLEAR-AKI: A multi-center, randomized, double blinded, placebo-controlled, four arm, parallel-group, dose-finding phase 2b study to investigate the safety and efficacy of TIN816 via a single intravenous infusion in the treatment of participants associated with sepsis- associated acute kidney injury (SA-AKI)
This study is looking into a new medicine, TIN816, for people who have kidney damage caused by sepsis. Researchers want to see if it's safe and helps the kidneys work better. Some people will get the medicine, others a dummy treatment.
For: Sepsis associated acute kidney injuryGermany · Austria · Czechia - Ongoing, recruitingTherapeutic exploratory (Phase II)
A randomized, multi-centric, placebo-controlled, participant and investigator-blinded study to evaluate the safety, tolerability and efficacy of TIN816 in adult patients at risk for acute kidney injury following cardiac surgery
This study is testing a new medicine, TIN816, for adults having heart surgery. It aims to see if TIN816 can protect kidneys from injury, which can sometimes happen after such operations. Researchers are checking how safe and effective the medicine is.
For: Acute kidney injurySpain · Germany · Czechia